Pharvaris develops drug candidates for hereditary angioedema, a rare condition that causes episodes of severe swelling. PHVS reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (9 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in PHVS, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 23 | B of A Securities | Upgrade | Buy | |
| Sep 10 | Guggenheim | Target raised | Buy | |
| Sep 9 | Morgan Stanley | Maintained | Buy | |
| Sep 9 | Leerink Partners | Maintained | Buy | |
| Sep 9 | Wells Fargo | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in PHVS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHVS is in one of them and how their past PHVS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PHVS in an article yet. Here's the latest on the wider market.
About Pharvaris N.V.
Pharvaris is a pharmaceutical company based in Leiden that is developing treatments for hereditary angioedema, a rare condition that causes episodes of severe swelling. Its product candidates, including IR and XR, are still in clinical development and have not yet received marketing approval. If approved, they would be sold to patients and physicians, with insurers and other payors deciding how much coverage to provide. The company intends them to be used alongside or in place of existing therapies.
- Headquarters
- Leiden